Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo.
OBJECTIVE
To assess the efficacy of topically applied CT-102 APST for treating diabetic neurotrophic foot ulcers.


METHODS
Thirteen patients entered a randomized, double-blind trial of topically applied CT-102 APST vs. placebo (normal saline) gauze dressings for the treatment of nonhealing diabetic neurotrophic foot ulcers. CT-102 APST (Curative Technologies, Setauket, NY) was prepared from homologous platelets and contained multiple growth factors including PDGF, PDAF, EGF, PF-4, TGF-beta, aFGF, and bFGF. Inclusion criteria for subjects included diabetes, ulcer of > 8 wk duration, peri-wound transcutaneous oxygen tension > 30 mmHg, platelet count > 100,000/mm3, and no wound infection. Wounds were excised before entry and were > 700 mm3 but < 50,000 mm3 in volume, < 100 cm2 in area, and involved subcutaneous tissue.


RESULTS
In the CT-102 group, 5 of 7 ulcers were healed (100% epithelialized) by 15 wk, but only 1 of 6 ulcers was healed by 20 wk with placebo (P < 0.05). Average percent reduction in ulcer area at 20 wk was 94% for CT-102 vs. 73% for placebo. Daily reduction in ulcer volume was 73.8 +/- 42.4 mm3/day (mean +/- SE) for CT-102 vs. 21.8 +/- 8.1 mm3/day for placebo (P < 0.05). Daily reduction in ulcer area was 6.2 +/- 1.8 mm2/day for CT-102 vs. 1.8 +/- 0.4 mm2/day for placebo (P < 0.05).


CONCLUSIONS
CT-102 significantly accelerated wound closure in diabetic leg ulcers when administered as part of a comprehensive program for the healing of chronic ulcers.
Steed
D L
DL
Department of Surgery, University of Pittsburgh, School of Medicine, Pennsylvania.
Goslen
J B
JB
Holloway
G A
GA
Malone
J M
JM
Bunt
T J
TJ
Webster
M W
MW
D002908:Chronic Disease; D045424:Complex Mixtures; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000503:physiopathology*; D004311:Double-Blind Method; D005260:Female; D016523:Foot Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D006133:Growth Substances / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D015539:Platelet Activation; D011446:Prospective Studies; D013997:Time Factors; D014945:Wound Healing
C078881:CT-102 activated platelet supernatant; D045424:Complex Mixtures; D006133:Growth Substances; D010919:Placebos